Rosuvastatin use reduces thrombin generation potential in patients with venous thromboembolism: a randomized controlled trial.
Adult
Aged
Aged, 80 and over
Blood Coagulation
/ drug effects
Female
Fibrinolytic Agents
/ adverse effects
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors
/ adverse effects
Male
Middle Aged
Netherlands
Recurrence
Rosuvastatin Calcium
/ adverse effects
Thrombin
/ metabolism
Time Factors
Treatment Outcome
Venous Thromboembolism
/ blood
Young Adult
hydroxymethylglutaryl-CoA reductase inhibitors
randomized clinical trial
thrombin generation
thrombophilia
venous thrombosis
Journal
Journal of thrombosis and haemostasis : JTH
ISSN: 1538-7836
Titre abrégé: J Thromb Haemost
Pays: England
ID NLM: 101170508
Informations de publication
Date de publication:
02 2019
02 2019
Historique:
received:
26
07
2018
pubmed:
20
12
2018
medline:
9
4
2020
entrez:
20
12
2018
Statut:
ppublish
Résumé
Essentials The role of statins in hemostasis and venous thromboembolism (VTE) prophylaxis is not clear. This trial assessed whether rosuvastatin use affects thrombin generation in patients with VTE. Endogenous thrombin potential and peak were decreased by 10% and 5% with rosuvastatin therapy. These results provide basis for trials on the efficacy of statins in reducing recurrent VTE risk. SUMMARY: Background Statin therapy could form an alternative prophylactic treatment for venous thromboembolism (VTE) if statins are proven to downregulate hemostasis and prevent recurrent VTE, without increasing bleeding risk. Objectives The STAtins Reduce Thrombophilia (START) trial investigated whether statin affects coagulation in patients with prior VTE. Patients/methods After anticoagulation withdrawal, patients were randomized to rosuvastatin 20 mg day
Identifiants
pubmed: 30565854
doi: 10.1111/jth.14364
pmc: PMC6850636
pii: S1538-7836(22)02467-9
doi:
Substances chimiques
Fibrinolytic Agents
0
Hydroxymethylglutaryl-CoA Reductase Inhibitors
0
Rosuvastatin Calcium
83MVU38M7Q
Thrombin
EC 3.4.21.5
Types de publication
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
319-328Subventions
Organisme : Dutch Heart Foundation
ID : NHS 2011T012
Pays : International
Organisme : São Paulo Research Foundation
ID : 2017/09506-5
Pays : International
Informations de copyright
© 2018 The Authors. Journal of Thrombosis and Haemostasis published by Wiley Periodicals, Inc. on behalf of International Society on Thrombosis and Haemostasis.
Références
Lancet Haematol. 2017 Feb;4(2):e83-e93
pubmed: 28089655
Eur Heart J. 2017 May 21;38(20):1608-1612
pubmed: 28369602
J Thromb Haemost. 2015 Sep;13(9):1642-52
pubmed: 26178257
Thromb Haemost. 2008 Aug;100(2):362-4
pubmed: 18690360
Int J Hematol. 2002 Oct;76(3):279-83
pubmed: 12416740
Clin Chem. 2016 May;62(5):699-707
pubmed: 26955824
J Thromb Haemost. 2008 Jan;6(1):125-31
pubmed: 17988231
BMJ. 2010 May 20;340:c2197
pubmed: 20488911
J Am Coll Cardiol. 2014 Jul 1;63(25 Pt B):2889-934
pubmed: 24239923
Thromb Haemost. 2016 Mar;115(3):520-32
pubmed: 26632869
Thromb Haemost. 2010 Jan;103(1):114-22
pubmed: 20062924
N Engl J Med. 2009 Apr 30;360(18):1851-61
pubmed: 19329822
J Thromb Haemost. 2019 Feb;17(2):319-328
pubmed: 30565854
J Thromb Haemost. 2005 Jul;3(7):1472-81
pubmed: 15978105
PLoS Med. 2012;9(9):e1001311
pubmed: 23028262
Chest. 2016 Feb;149(2):315-352
pubmed: 26867832
J Am Coll Cardiol. 1999 Apr;33(5):1286-93
pubmed: 10193729
Eur Heart J. 2014 Nov 14;35(43):3033-69, 3069a-3069k
pubmed: 25173341
Thromb Res. 2012 Apr;129 Suppl 1:S6-9
pubmed: 22682135
Thromb Haemost. 2015 Aug 31;114(3):546-57
pubmed: 26017749
J Thromb Haemost. 2008 Oct;6(10):1720-5
pubmed: 18680535
Expert Rev Hematol. 2016 Nov;9(11):1023-1030
pubmed: 27759438
Thromb Haemost. 2008 Aug;100(2):240-5
pubmed: 18690343
J Thromb Haemost. 2014 Oct;12(10):1580-90
pubmed: 25302663
Obstet Gynecol. 2010 May;115(5):1063-1070
pubmed: 20410783
J Thromb Haemost. 2016 Jul;14(7):1374-83
pubmed: 27079164
J Thromb Haemost. 2005 Jun;3(6):1243-9
pubmed: 15946215
Thromb Haemost. 1994 Aug;72(2):222-6
pubmed: 7831656
Thromb Haemost. 2002 Jul;88(1):41-7
pubmed: 12152675
PLoS One. 2012;7(3):e32894
pubmed: 22470429
Am J Clin Pathol. 2015 Feb;143(2):241-7
pubmed: 25596250
Thromb Res. 2013 Jan;131(1):3-11
pubmed: 23158401
JAMA. 2006 Jul 26;296(4):397-402
pubmed: 16868297
Arch Intern Med. 2005 May 23;165(10):1147-52
pubmed: 15911728
Br J Haematol. 2008 Sep;142(6):889-903
pubmed: 18564356
J Thromb Haemost. 2013 Jun;11(6):1078-84
pubmed: 23565981
Thromb Haemost. 2014 Mar 3;111(3):392-400
pubmed: 24285296
Proc Natl Acad Sci U S A. 1988 Nov;85(21):8227-30
pubmed: 2847155
Clin Chem. 2008 Dec;54(12):2042-8
pubmed: 18948369
Arterioscler Thromb Vasc Biol. 2003 Jan 1;23(1):17-25
pubmed: 12524220
Blood. 2014 Mar 20;123(12):1794-801
pubmed: 24497538
Lancet Haematol. 2016 Sep;3(9):e426-36
pubmed: 27570089
Br J Haematol. 2007 Sep;138(6):769-74
pubmed: 17760809
J Thromb Haemost. 2008 Aug;6(8):1327-33
pubmed: 18485081
J Thromb Haemost. 2009 Oct;7(10):1639-48
pubmed: 19656279
PLoS Med. 2012;9(9):e1001310
pubmed: 23028261
Eur Heart J. 2018 May 14;39(19):1740-1747
pubmed: 29394348
Thromb Res. 2011 Nov;128(5):422-30
pubmed: 21641019
Res Pract Thromb Haemost. 2017 Oct 16;2(1):42-48
pubmed: 30046705
Thromb Res. 2012 Mar;129(3):367-70
pubmed: 22079443